Possible FRAX-based intervention thresholds for a cohort of Chinese postmenopausal women

FRAX updates 2012

(2012) Eugene McCloskey et al.   CURRENT OPINION IN RHEUMATOLOGY

2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis

(2012) Karine Briot et al.   JOINT BONE SPINE

The distribution of FRAX®-based probabilities in women from Japan

(2012) John A. Kanis et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX

(2012) Eugene V McCloskey et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland

(2012) K. Lippuner et al.   OSTEOPOROSIS INTERNATIONAL

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

(2012) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary

(2012) Hajime Orimo et al.   Archives of Osteoporosis

FRAX® with and without Bone Mineral Density

(2011) John A. Kanis et al.   CALCIFIED TISSUE INTERNATIONAL

Pitfalls in the external validation of FRAX

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Discriminative value of FRAX for fracture prediction in a cohort of Chinese postmenopausal women

(2011) E. Y. N. Cheung et al.   OSTEOPOROSIS INTERNATIONAL

Disparate Outcomes from Applying U.K. and U.S. Osteoporosis Treatment Guidelines

(2010) Mark J. Bolland et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®

(2009) John A. Kanis et al.   BONE

Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

(2009) J. Compston et al.   MATURITAS

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™)

(2008) S. Fujiwara et al.   OSTEOPOROSIS INTERNATIONAL

Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study

(2008) E. V. McCloskey et al.   OSTEOPOROSIS INTERNATIONAL

Cost-effective osteoporosis treatment thresholds: the United States perspective

(2008) A. N. A. Tosteson et al.   OSTEOPOROSIS INTERNATIONAL

Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks

(2008) N. D. Nguyen et al.   OSTEOPOROSIS INTERNATIONAL

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA

(2008) B. Dawson-Hughes et al.   OSTEOPOROSIS INTERNATIONAL

Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL